PINK
SGIOY

Shionogi & Co Ltd ADR

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Shionogi & Co Ltd ADR Stock Price

Vitals

Today's Low:
$10.96
Today's High:
$11.08
Open Price:
$11
52W Low:
$10.1
52W High:
$14.13
Prev. Close:
$10.91
Volume:
83400

Company Statistics

Market Cap.:
$13.00 billion
Book Value:
994.223
Revenue TTM:
$464.16 billion
Operating Margin TTM:
41.67%
Gross Profit TTM:
$279.72 billion
Profit Margin:
41.54%
Return on Assets TTM:
9.43%
Return on Equity TTM:
17.26%

Company Profile

Shionogi & Co Ltd ADR had its IPO on under the ticker symbol SGIOY.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Shionogi & Co Ltd ADR has a staff strength of 5,680 employees.

Stock update

Shares of Shionogi & Co Ltd ADR opened at $11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $10.96 - $11.08, and closed at $11.04.

This is a +1.19% increase from the previous day's closing price.

A total volume of 83,400 shares were traded at the close of the day’s session.

In the last one week, shares of Shionogi & Co Ltd ADR have increased by +0.78%.

Shionogi & Co Ltd ADR's Key Ratios

Shionogi & Co Ltd ADR has a market cap of $13.00 billion, indicating a price to book ratio of 2.0155 and a price to sales ratio of 0.0443.

In the last 12-months Shionogi & Co Ltd ADR’s revenue was $464.16 billion with a gross profit of $279.72 billion and an EBITDA of $210.66 billion. The EBITDA ratio measures Shionogi & Co Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Shionogi & Co Ltd ADR’s operating margin was 41.67% while its return on assets stood at 9.43% with a return of equity of 17.26%.

In Q2, Shionogi & Co Ltd ADR’s quarterly earnings growth was a positive 25.6% while revenue growth was a positive 52.2%.

Shionogi & Co Ltd ADR’s PE and PEG Ratio

Forward PE
15.5039
Trailing PE
10.0364
PEG

Its diluted EPS in the last 12-months stands at $1.1 per share while it has a forward price to earnings multiple of 15.5039 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Shionogi & Co Ltd ADR’s profitability.

Shionogi & Co Ltd ADR stock is trading at a EV to sales ratio of 0.0334 and a EV to EBITDA ratio of 0.0706. Its price to sales ratio in the trailing 12-months stood at 0.0443.

Shionogi & Co Ltd ADR stock pays annual dividends of $135 per share, indicating a yield of 2.19% and a payout ratio of 20.53%.

Balance sheet and cash flow metrics

Total Assets
$1,363.78 billion
Total Liabilities
$140.12 billion
Operating Cash Flow
$0
Capital Expenditure
$6.32 billion
Dividend Payout Ratio
20.53%

Shionogi & Co Ltd ADR ended 2024 with $1,363.78 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1,363.78 billion while shareholder equity stood at $1,170.42 billion.

Shionogi & Co Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $140.12 billion in other current liabilities, 21279000000.00 in common stock, $961.29 billion in retained earnings and $9.89 billion in goodwill. Its cash balance stood at $289.08 billion and cash and short-term investments were $576.39 billion. The company’s total short-term debt was $3,079,000,000 while long-term debt stood at $0.

Shionogi & Co Ltd ADR’s total current assets stands at $783.28 billion while long-term investments were $0 and short-term investments were $287.31 billion. Its net receivables were $115.51 billion compared to accounts payable of $15.30 billion and inventory worth $62.60 billion.

In 2024, Shionogi & Co Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $6.32 billion.

Comparatively, Shionogi & Co Ltd ADR paid $0.21 in dividends in 2024.

Other key metrics

Current Trading Price
$11.04
52-Week High
$14.13
52-Week Low
$10.1
Analyst Target Price
$

Shionogi & Co Ltd ADR stock is currently trading at $11.04 per share. It touched a 52-week high of $14.13 and a 52-week low of $14.13. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $10.64 and 200-day moving average was $11.35 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 15.7% are held by institutions.

Frequently Asked Questions About Shionogi & Co Ltd ADR

The stock symbol (also called stock or share ticker) of Shionogi & Co Ltd ADR is SGIOY

The IPO of Shionogi & Co Ltd ADR took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$10.41
-0.04
-0.38%
$556.9
-22.5
-3.88%
$2.78
0.18
+6.92%
$176.1
-5.65
-3.11%
$3359.5
-331.65
-8.99%
$6.21
0.13
+2.14%
$6.63
-0.34
-4.88%
$234
0
0%
IMP POWERS LTD. (INDLMETER)
$4.94
-0.26
-5%
$1552.25
-81.65
-5%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay, an anti-HIV drug. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, and Refractory/unexplained chronic cough; Zuranolone for Depression; SDT-001, Inattentive ADHD pediatric; BPN14770 for Alzheimer’s disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamous cell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Address

1-8, Doshomachi 3-chome, Osaka, Japan, 541-0045